Search GMED
GLOBUS MEDICAL INC
NYSE · CIK 1237831
Last close75.6
Daily change+1.19 (1.60%)
10 Years gain+233.33%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
GMED · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
60.4Momentum
98.0Acceleration
94.0Confidence
91.0Annual Revenue16
Quarterly Revenue68
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth24.6 / 25
Quality7.2 / 25
Capital Efficiency8.6 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Gross margin expansionGross margin improved by 7.4424 percentage points.
Operating leverageOperating margin improved by 9.5901 percentage points.
ROIC expansionROIC improved by 7.6035 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 1.7099%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM24.54%OK
Revenue CAGR 3Y42.17%OK
Gross Margin68.12%OK
Operating Margin17.83%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC11.72%OK
Incremental Operating Margin 3Y15.93%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-1.71%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $2.94B | $1.98B | $479.82M | $753.45M | $588.77M | 67.41% | 16.33% | 20.03% | 11.68% | 137.06M |
| 2025 FY Dec 31, 2024 | $2.52B | $1.48B | $165.99M | $520.64M | $405.21M | 58.9% | 6.59% | 16.08% | 4.18% | 137.86M |
| 2025 FY Dec 31, 2023 | $1.57B | $1.02B | $133.14M | $243.50M | $165.23M | 65.05% | 8.49% | 10.53% | 4.05% | 114.63M |
| 2024 FY Dec 31, 2022 | $1.02B | $759.12M | $227.95M | $178.47M | $104.42M | 74.22% | 22.29% | 10.21% | 13.22% | 102.64M |
| 2023 FY Dec 31, 2021 | $958.10M | $718.88M | $171.95M | $276.27M | $219.38M | 75.03% | 17.95% | 22.9% | 11.96% | 103.62M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $3.06B | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-054450, 0001237831-25-000031 |
| Revenue Growth TTM | 24.54% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-054450, 0001237831-25-000031 |
| Revenue CAGR 3Y | 42.17% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-011209 |
| Revenue CAGR 5Y | 30.08% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-011209 |
| Gross Profit CAGR 3Y | 37.68% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-011209 |
| Operating Income Growth | 169.48% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001628280-26-054450, 0001237831-25-000031 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 68.12% | Gross Profit / Revenue | OK | 0001628280-26-054450, 0001237831-25-000031 |
| Operating Margin | 17.83% | Operating Income / Revenue | OK | 0001628280-26-054450, 0001237831-25-000031 |
| ROIC | 11.72% | NOPAT / Average Invested Capital | OK | 0001628280-26-054450, 0001237831-25-000031 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-054450 |
| Current Ratio | 4.62x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $22.30 | Revenue / Diluted Shares | OK | 0001628280-26-054450, 0001237831-25-000031 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |